Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074463 | 1.00 | RXRA (0.42) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL5782136 | 0.84 | ALDH1A1 (0.58) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL679095 | 0.84 | ALDH1A1 (0.50) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL20844170 | 0.81 | CA1 (0.42) | ALDH1A1RAB9AMAPTCYP3A4KDM4E | |
| SCHEMBL16094031 | 0.78 | HTT (0.42) | ALDH1A1L3MBTL1TLR8KDM4EKMT2A | |
| SCHEMBL2522090 | 0.77 | RXRA (0.43) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL257565 | 0.77 | RXRA (0.43) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL12255396 | 0.77 | RXRA (0.43) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL30181252 | 0.77 | RXRA (0.43) | RXRARXRBRXRGALDH1A1PTGS1 | |
| SCHEMBL388181 | 0.77 | ALDH1A1 (0.69) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20240246969-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-25 | — | — | US | disclosed |
| EP-4337660-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117597345-A | Heterocyclic derivatives as CaMKK2 inhibitors | 百时美施贵宝公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-1737811-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008011109-A2 | SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011109-A2 | SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| CN-1942428-A | CETP inhibitors | MERCK & CO INC (US) | 2007-04-04 | — | — | CN | disclosed |
| EP-1737811-A1 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100298-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-5196422-A | Antiinflammatory agents, antiallergens | ICI PHARMA (FR) | 1993-03-23 | — | — | US | disclosed |
| US-5089513-A | Antiinflammatory agents; antiallergens; asthma; side effect reduction | ICI PHARMA (FR) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | RXRA 3077/4885RXRB 2771/4885RXRG 3206/4885 |
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | RXRA 2001/4885RXRB 2413/4885RXRG 1901/4885 |
| US-20240246969-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | CAMKK2, CAMKK1, CAMK1 | RXRA 3375/4885RXRB 3262/4885RXRG 2568/4885 |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | KIT, CMA1, C3AR1 | RXRA 3094/4885RXRB 2442/4885RXRG 2721/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | RXRA 3077/4885RXRB 2771/4885RXRG 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.